These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 20731110)

  • 1. [Antihypertensive therapy optimization and endothelial function in patients with gout and chronic urate tubulointerstitial nephritis].
    Lebedeva MV; Stakhova TIu; Zaĭtseva LI; Selivanova OIu; Severova MM
    Ter Arkh; 2010; 82(6):43-6. PubMed ID: 20731110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function.
    Morimoto S; Maki K; Aota Y; Sakuma T; Iwasaka T
    Hypertens Res; 2008 Aug; 31(8):1603-10. PubMed ID: 18971536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rationale for treatment of endothelial dysfunction in hypertension.
    Ruschitzka F; Corti R; Noll G; Lüscher TF
    J Hypertens Suppl; 1999 Feb; 17(1):S25-35. PubMed ID: 10340841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combination therapy of antihypertensive drugs].
    Ruskoaho H
    Duodecim; 1996; 112(13):1205-8. PubMed ID: 10596089
    [No Abstract]   [Full Text] [Related]  

  • 5. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
    Jamerson KA; Nwose O; Jean-Louis L; Schofield L; Purkayastha D; Baron M
    Am J Hypertens; 2004 Jun; 17(6):495-501. PubMed ID: 15177521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Kidney involvement in gout].
    Stein G
    Beitr Rheumatol; 1972; 18():61-7. PubMed ID: 4649120
    [No Abstract]   [Full Text] [Related]  

  • 7. A rational approach to hypertension treatment in the older patient.
    Flack JM; Woolley A; Esunge P; Grimm RH
    Geriatrics; 1992 Nov; 47(11):24-8, 33-8. PubMed ID: 1358761
    [No Abstract]   [Full Text] [Related]  

  • 8. Spironolactone and chlorthalidone in uncontrolled elderly hypertensive patients treated with calcium antagonists and angiotensin II receptor-blocker: effects on endothelial function, inflammation, and oxidative stress.
    Yamanari H; Nakamura K; Miura D; Yamanari S; Ohe T
    Clin Exp Hypertens; 2009 Oct; 31(7):585-94. PubMed ID: 19886856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fixed-dose combination therapy in the treatment of hypertension: ready for prime time.
    Basile JN
    South Med J; 2007 Apr; 100(4):343-4. PubMed ID: 17458389
    [No Abstract]   [Full Text] [Related]  

  • 10. [Medical treatment of hypertension--what treatment for what patients?].
    Zidek W; Tepel M; van der Giet M
    MMW Fortschr Med; 2004 May; 146(22):31-4. PubMed ID: 15373106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of patients with arterial hypertension in Moscow].
    Iurenev AP; Patrusheva IF; Smirnova MD; Kunnova LM
    Ter Arkh; 2001; 73(9):31-4. PubMed ID: 11642077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting endothelial dysfunction in hypertensive subjects.
    Thuillez C; Richard V
    J Hum Hypertens; 2005 Jun; 19 Suppl 1():S21-5. PubMed ID: 16075029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hypertension therapies compared. Are the new nevertheless better than the old?].
    MMW Fortschr Med; 2005 Mar; 147(12):6, 8. PubMed ID: 15832780
    [No Abstract]   [Full Text] [Related]  

  • 14. Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor-markers of endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors.
    Hlubocká Z; Umnerová V; Heller S; Peleska J; Jindra A; Jáchymová M; Kvasnicka J; Horký K; Aschermann M
    J Hum Hypertens; 2002 Aug; 16(8):557-62. PubMed ID: 12149661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive drugs and fibrinolytic function.
    Fogari R; Zoppi A
    Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Renin-angiotensin-aldosterone system inhibition: pharmacologic rationale and evaluations of drug combinations].
    Andréjak M; Slama M; Hary L
    Therapie; 1998; 53(3):291-300. PubMed ID: 9773129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The "Furberg bias" or: about the arbitrary handling of evidence-based medicine].
    Middeke M
    Dtsch Med Wochenschr; 2001 Feb; 126(6):151-2. PubMed ID: 11233884
    [No Abstract]   [Full Text] [Related]  

  • 18. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of trandolapril alone or in combination with a calcium channel blocker in hypertensive patients over 60 years of age].
    Gosse P; Vaur L; Dutrey-Dupagne C; Genes N; Destrée D; Elkik F
    Ann Cardiol Angeiol (Paris); 1995 Nov; 44(9):517-24. PubMed ID: 8745662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Revised guidelines for antihypertensive treatment. What is relevant for the general practitioner?].
    Zidek W
    MMW Fortschr Med; 2004 Jan; 146(1-2):37-8. PubMed ID: 18437867
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.